Skip to content

Author

R. van Dams

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Impact of Institutional Radiotherapy Patient Volume on Postoperative and Oncologic Outcomes After Neoadjuvant Radiation for Pancreatic Cancer.

INTRODUCTION Neoadjuvant radiation therapy (NRT) is beneficial in gastrointestinal cancers, but its role in pancreatic ductal adenocarcinoma (PDAC) remains uncertain. It is unclear if hospital-level NRT volume is an important factor when treating PDAC with NRT. METHODS The National Cancer Database (2011-2019) was use...

A. Pannekoek, R. Narayan, Amanda Carlson et al. · 0 citations
Review Oct 2026

Pancreatic Reirradiation: A Multi-Institutional Retrospective Analysis of Feasibility, Tolerability, and Clinical Outcomes.

Pancreatic re-RT is feasible and may offer promising local control and time off chemotherapy for selected patients, and improvements in RT delivery with online adaptive therapy may further minimize toxicity.

Helen X. Hou, Hannah J. Roberts, P. Pathak et al. · 0 citations
Open access Sep 2026

CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC) is refractory to most therapies, including immunotherapies, for which reinvigoration of CD8 T cells through immune checkpoint blockade is insufficient to induce long-term, durable remissions. Direct KRAS inhibitors (KRASi) have shown clinical promise, although acquired resistance...

Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.